AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best Canadian stocks with huge upside potential. Earlier in May, AbCellera Biologics announced that the US Court of Appeals for the Federal Circuit ...

AbCellera Biologics' drug candidates in Phase 1 trials show promise, but financial losses and slow progress raise concerns.

AbCellera announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL575, an investigational antibody antagonist targeting OX40 ...

AbCellera Biologics Inc. (ABCL)’s share was trading at $2.14 as of 2nd June. ABCL’s trailing P/E was 19.92 according to Yahoo Finance. Abcellera is approaching a potential inflection point ...

We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Investment Ides by Antonio’s Substack. In this article, we will summarize the bulls’ thesis on ABCL. AbCellera Biologics Inc.

ABCELLERA BIOLG (ABCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Investors were surely discovering drug discovery company AbCellera Biologics (NASDAQ: ABCL) as the trading week kicked off on Monday. On encouraging news in an important North American jurisdiction, ...

Investors were surely discovering drug discovery company AbCellera Biologics (NASDAQ: ABCL) as the trading week kicked off on Monday. On encouraging news in an important North American ...

Details on AbCellera’s poster presentation at SID are as follows: Title : Preclinical development of ABCL575, a half-life extended anti-OX40L monoclonal antibody for the treatment of autoimmune ...

About Absci Corp. Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partne ...

AbCellera announced today that it has expanded its existing collaboration with AbbVie Inc. to include the discovery of T-cell engagers in oncology. The expansion builds upon the successful ...

AbCellera Biologics (ABCL-2.16%) Q3 2024 Earnings Call Nov 04, 2024, 5:00 p.m. ET. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Good afternoon ...